Also listed under Myeloproliferative Disorders
ClinicalTrials.gov term: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia (CML) clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
26 trials changed in the last 30 days: 3 stopped, 13 with notable changes, 10 with minor changes only.
- Stopped: HA-1 T TCR T Cell Immunotherapy · Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruitment suspended
- Notable: Dasatinib in Combination With Ropeginterferon · Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Phase changed: Phase 2 → Phase 1/2
- Notable: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Primary completion pushed from Nov 1, 2026 to Jun 1, 2027
- Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended
- Notable: APTBCy · Optimization of Post-transplantation Benadamustine and Cyclophosphamide · High-risk Myeloid Malignancies and a Partially Mismatched Donor Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027
- Notable: ENABLE-2 · ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs Recruitment opened
- Minor: VitaStem · Vitamin A and D Supplementation in Allogeneic HCT Enrollment closed, study ongoing
- Notable: Allogeneic iNKT Cell Therapy (agenT-797) After SCT Recruitment opened
- Notable: ESTIMATION · Asciminib in Chronic Phase CML · T315I Mutations Enrollment reopened
- Notable: ASC4Young · Asciminib Safety and Efficacy in Young · Chronic Myeloid Leukemia in the Gulf Region Start date pushed from Oct 29, 2026 to Dec 1, 2026
- Notable: Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait Start date pushed from Oct 30, 2026 to Jan 31, 2027
- Minor: Asciminib · Ph+ CML-CP Trial sites expanded: 34 → 39 locations
- Minor: Asciminib · Chronic Myeloid Leukemia Enrollment closed, study ongoing
- Minor: Asciminib Roll-over Study Trial sites expanded: 85 → 88 locations
- Minor: ASC2ADHERE · Asciminib · Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany Trial sites expanded: 69 → 74 locations
- Minor: K2SPIRIT · Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation
- Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated
- Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations
- Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026
- Notable: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Primary completion pushed from Sep 2026 to Sep 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-14 | NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms | John Mascarenhas new | Phase 2 |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-09-04 | NCT07804901 Asciminib Frontline Risk Adapted | Prof. Dr. med. Andreas Hochhaus new | Phase 2 |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 32 | |
| Phase 1/2 | 13 | |
| Phase 2 | 64 | |
| Phase 3 | 9 | |
| Phase 4 | 3 |
Not charted: 56 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
M.D. Anderson Cancer Center (18) · Novartis Pharmaceuticals (15) · City of Hope Medical Center (7) · Assiut University (5) · Baylor College of Medicine (4) · Center for International Blood and Marrow Transplant Research (4) · Fred Hutchinson Cancer Center (4) · Shenzhen TargetRx Co., Ltd. (4) · Enliven Therapeutics (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3)
Get alerts when Chronic Myeloid Leukemia (CML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.